The role of inhaled long-acting beta-2 agonists in the management of asthma

Journal of the National Medical Association

Volumn 98, Issue 1, 2006, Pages 8-16

  Kelly, H William ^a   Harkins, Michelle S ^a,c   Boushey, Homer ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Lung; Polymorphisms

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; NEDOCROMIL; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE DERIVATIVE; ZAFIRLUKAST;

ASTHMA; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG INDICATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LOW DRUG DOSE; META ANALYSIS; MILD INTERMITTENT ASTHMA; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEVERE PERSISTENT ASTHMA; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS;

EID: 30444447201     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. National Heart Lung Blood Institute. National Asthma Education Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: Government Printing Office; 1997. National Institutes of Health Publication No. 97-4051.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. 2002. Bethesda, MD; 2002. NIH Publication No. 02-3659.
3. NHLBI. Executive Summary of the NAEPP Expert Panel Report: Guidelines for the diagnosis and management of asthma-update on selected topics Bethesda, MD; 2002. NIH publication No. 02-5075. www.nhlbi.nih.gov.
4. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720-1745.
5. Folkerts G, Busse WW, Nijkamp FP, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 1998;157:1708-1720.
6. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;308:982-986.
7. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159:1043-1051.
8. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV, is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107:61-67.
9. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
10. Weiss KB, Sullivan SD, Lyttle S. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000;106:493-499.
11. Greening AP, Wind P, Northfield M, et al. Added salmeterol versus high-er-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
12. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488.
13. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-1397.
14. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
15. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA), BMJ. 2000;320:1368-1373.
16. Agency for Healthcare Research and Quality, Management of Chronic Asthma, Evidence Report/Technology Assessment, Number 44, 2001. AHRQ Publication No.01-E044.www.ahrq.gov.
17. Anderson GP. Interactions between corticosteroids and B-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am J Respir Crit Care Med. 2000;161:S188-S196.
18. Naline E, Zhang Y, Qien Y, et al. Relaxant effects and duration of action of formoterol and salmeterol on the isolated human bronchus, Eur Respir J. 1994;7:914-920.
19. Rabe KF, Jorres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis. 1993;147:1436-1441.
20. Roux FJ, Grandordy B, Douglas JS. Functional and binding characteristics of long-acting beta-2-agonists in lung and heart. Am J Respir Crit Care Med. 1996;153:1489-1495.
21. Kips JC, Pauwels RA. Long-acting inhaled beta-2-agonist therapy in asthma. Am J Respir Crit Care Med. 2001;164:923-932.
22. Wong BJ, Dolovich J, Ramsdale EH, et al. Formoterol compared with beclomethasone and placebo on allergen- induced asthmatic responses. Am Rev Respir Dis. 1992;146:1156-1160.
23. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000;55:650-656.
24. Palmqvist M, Ibsen T, Mellon A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999;160:244-249.
25. Bartow RE, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs, 1998;55:303-322.
26. Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of long-acting beta-2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327:1198-1203.
27. Jones SL, Cowan JO, Flannery EM, et al. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J. 2001;17:368-373.
28. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate bronchoconstriction during high dose treatment with long acting beta-2 agonists. Thorax. 2001;56:529-535.
29. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest. 2000;117:156-162.
30. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med. 1992;327:1420-1425.
31. FitzGerald JM, Chapman KR, Cioppa GD, et al. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427-435.
32. Hoecki MA, Hinz GW, Medici TC. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest. 1997;14:165-174.
33. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet. 2004;364:1505-1512.
34. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta-2 adrenoreceptor polymorphism. Thorax. 2000;55:762-767.
35. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as needed use of albuterol in mild asthma. N Engl J Med, 1996;335:841-847.
36. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial, Lancet, 2000;355:1675-1679.
37. Israel E, Drazen JM, Liggott SB, et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75-80.
38. Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest, 1999;116:595-602.
39. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta-2 agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593.
40. 1, shortly after cessation of the beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2 agonists. Respir Med. 2002;96:155-162.
41. Calhoun WJ, Hinton KL, Karatzenburg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med. 2001;163:881-886.
42. Lindqvist A, Karjalainen E-M, Laitinen LA, et al. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium-cromoglycate. J Allergy Clin Immunol. 2003;112:23-28.
43. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19-27.
44. Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 mg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med. 2001;95:64-70.
45. Cloosterman SGM, Bijl-Hofland ID, van Herwaarden CLA, et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta-2-agonists in allergic asthmatic patients. Chest. 2001;119:1306-1315.
46. Fjellbirteland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airway disease. Respir Med. 1994;88:599-607.
47. Paggiaro PL, Giannini D, Di Franco A, et al. Comparison of inhaled salmeterol and individually dose-titrated slow release theophylline in patients with reversible airway obstruction. Eur Respir J. 1996;9:1689-1695.
48. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med. 1997;337:1659-1665.
49. Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Off Care Med. 1997;156:688-695.
50. Medwatch: www.fda.gov/medwatch/2003/serevent.htm.
51. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994;88:363-368.
52. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339:141-146.
53. van Noord JA, Schreurs AJM, Mol SJM, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999;54:207-212.
54. Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J. 1999;14:627-632.
55. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma-a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med. 1999;160:594-599.
56. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med. 2000;161:996-1001.
57. Wallin A, Sue-Chu M, Bjermer L et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 2003;112:72-78.
58. Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med. 2001;95:505-512.
59. Heuck C, Heickendorff, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child. 2000;83:334-339.
60. Lemanske Jr RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285(20):2594-2603.
61. Kelloway JS, Wyatt R, DeMarco J, et al. Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. Ann Allergy Asthma Immunol. 2000;84:324-328.
62. van der Woude HJ, Aalbers R. Compliance with inhaled glucocorticoids and concomitant use of long-acting beta-2-agonists. Respir Med. 2001;95:404-407.
63. Busse W, Nelson J, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma, J Allergy Clin Immunol. 1999;103:1075-1080.
64. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000;106:1088-1095.
65. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001;120:423-430.